Series Overview

As new therapies for relapsed or refractory multiple myeloma (RRMM) are approved and patient treatment history grows more complex, clinicians often seek out colleagues for advice on certain patients or scenarios. This series of Phone-a-Friend episodes features 2 MM experts asking and addressing common questions about topics related to bispecific antibody therapies. The series will cover a variety of topics, including determining eligibility for bispecific antibody therapy, using clinical evidence to select an agent, and practical considerations for implementing treatment and managing adverse events.  Each episode is centered around a specific patient.

Target Audience

This series is intended for hematologic oncology clinicians including physicians, fellows, nurse practitioners (NPs), nurses, and physician associates (PAs), in both the academic as well as the community setting.


Webcast Series 
0.25 CME/CE

When and How to Choose Bispecific Antibody Therapy in Relapsed or Refractory Multiple Myeloma

Webcast Series 
0.25 CME/CE

Getting Started: Incorporating Bispecifics Into Clinical Practice

available resources
linked resources
Suggested Reading

Making the Call in Relapsed or Refractory Multiple Myeloma

Incorporating Bispecific Antibody Therapy Into Practice